 Nancy Reau
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 28 | 2021 | 83 | 9.860 |
Why?
| | Antiviral Agents | 31 | 2021 | 139 | 8.960 |
Why?
| | Hepatitis C | 18 | 2021 | 67 | 6.380 |
Why?
| | Hepacivirus | 21 | 2021 | 73 | 5.040 |
Why?
| | Liver Transplantation | 8 | 2021 | 110 | 3.640 |
Why?
| | Liver Diseases | 9 | 2021 | 40 | 3.370 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2020 | 35 | 2.290 |
Why?
| | Ribavirin | 9 | 2016 | 32 | 2.020 |
Why?
| | Pregnancy Complications | 5 | 2019 | 57 | 1.930 |
Why?
| | Infectious Disease Transmission, Vertical | 3 | 2020 | 20 | 1.860 |
Why?
| | Liver Cirrhosis | 10 | 2019 | 61 | 1.660 |
Why?
| | Sulfonamides | 7 | 2020 | 66 | 1.480 |
Why?
| | Hepatitis B | 5 | 2019 | 20 | 1.470 |
Why?
| | Interferon-alpha | 5 | 2012 | 82 | 1.410 |
Why?
| | Polyethylene Glycols | 5 | 2012 | 57 | 1.410 |
Why?
| | Pregnancy | 10 | 2021 | 452 | 1.380 |
Why?
| | Humans | 56 | 2021 | 30741 | 1.250 |
Why?
| | Carbamates | 9 | 2020 | 12 | 1.170 |
Why?
| | Quinoxalines | 5 | 2020 | 11 | 1.100 |
Why?
| | Drug Therapy, Combination | 13 | 2021 | 266 | 1.070 |
Why?
| | Treatment Outcome | 20 | 2021 | 3850 | 0.970 |
Why?
| | Gastroenterology | 3 | 2017 | 16 | 0.960 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2021 | 44 | 0.940 |
Why?
| | Living Donors | 1 | 2021 | 16 | 0.920 |
Why?
| | Prejudice | 1 | 2021 | 42 | 0.900 |
Why?
| | United States | 16 | 2021 | 2467 | 0.890 |
Why?
| | Female | 33 | 2021 | 18107 | 0.890 |
Why?
| | Thrombocytopenia | 1 | 2020 | 31 | 0.850 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 30 | 0.840 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 54 | 0.840 |
Why?
| | Benzimidazoles | 3 | 2019 | 14 | 0.830 |
Why?
| | Patient Selection | 1 | 2021 | 259 | 0.810 |
Why?
| | Kidney Transplantation | 2 | 2018 | 144 | 0.800 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2019 | 2 | 0.790 |
Why?
| | Genotype | 10 | 2017 | 447 | 0.780 |
Why?
| | Viral Load | 5 | 2016 | 211 | 0.750 |
Why?
| | Algorithms | 2 | 2020 | 421 | 0.730 |
Why?
| | Fear | 1 | 2018 | 52 | 0.720 |
Why?
| | Cholestasis, Intrahepatic | 3 | 2019 | 6 | 0.720 |
Why?
| | Obesity | 1 | 2021 | 322 | 0.720 |
Why?
| | Adult | 21 | 2021 | 9760 | 0.680 |
Why?
| | HIV Infections | 3 | 2019 | 915 | 0.650 |
Why?
| | Drugs, Generic | 1 | 2016 | 4 | 0.650 |
Why?
| | Antacids | 1 | 2016 | 1 | 0.650 |
Why?
| | Proton Pump Inhibitors | 1 | 2016 | 15 | 0.640 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2016 | 4 | 0.640 |
Why?
| | Virology | 1 | 2015 | 16 | 0.620 |
Why?
| | Middle Aged | 21 | 2021 | 11256 | 0.580 |
Why?
| | Patient Readmission | 1 | 2016 | 124 | 0.560 |
Why?
| | Length of Stay | 2 | 2016 | 371 | 0.550 |
Why?
| | Coinfection | 3 | 2019 | 33 | 0.550 |
Why?
| | Young Adult | 9 | 2021 | 2249 | 0.530 |
Why?
| | Preventive Health Services | 1 | 2013 | 15 | 0.530 |
Why?
| | Mass Screening | 5 | 2021 | 199 | 0.520 |
Why?
| | Advisory Committees | 1 | 2013 | 43 | 0.510 |
Why?
| | Health Policy | 1 | 2013 | 49 | 0.500 |
Why?
| | Cyclopropanes | 4 | 2020 | 25 | 0.490 |
Why?
| | Heart Failure | 1 | 2016 | 231 | 0.490 |
Why?
| | Male | 23 | 2021 | 17552 | 0.480 |
Why?
| | Disease Management | 2 | 2016 | 149 | 0.470 |
Why?
| | Liver | 2 | 2018 | 216 | 0.460 |
Why?
| | Imidazoles | 4 | 2020 | 74 | 0.430 |
Why?
| | Macrocyclic Compounds | 4 | 2019 | 6 | 0.420 |
Why?
| | Pregnancy Outcome | 2 | 2021 | 20 | 0.420 |
Why?
| | Recombinant Proteins | 5 | 2012 | 308 | 0.420 |
Why?
| | Drug Resistance, Viral | 4 | 2017 | 43 | 0.410 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2008 | 7 | 0.370 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 271 | 0.360 |
Why?
| | Aged | 14 | 2020 | 10156 | 0.360 |
Why?
| | Fatty Liver | 2 | 2019 | 40 | 0.350 |
Why?
| | Anemia | 1 | 2008 | 91 | 0.350 |
Why?
| | Retrospective Studies | 8 | 2020 | 3456 | 0.340 |
Why?
| | Cohort Studies | 6 | 2021 | 1959 | 0.340 |
Why?
| | Medication Adherence | 2 | 2019 | 93 | 0.330 |
Why?
| | Liver Neoplasms | 2 | 2019 | 128 | 0.320 |
Why?
| | Liver Function Tests | 2 | 2019 | 32 | 0.320 |
Why?
| | Benzofurans | 3 | 2020 | 8 | 0.310 |
Why?
| | Risk Factors | 4 | 2020 | 2611 | 0.300 |
Why?
| | Graft Rejection | 2 | 2018 | 85 | 0.300 |
Why?
| | Prevalence | 2 | 2020 | 546 | 0.290 |
Why?
| | Societies, Medical | 2 | 2017 | 203 | 0.280 |
Why?
| | Adolescent | 4 | 2020 | 2627 | 0.280 |
Why?
| | Lactams, Macrocyclic | 3 | 2019 | 9 | 0.280 |
Why?
| | Drug Interactions | 2 | 2015 | 71 | 0.280 |
Why?
| | Proline | 3 | 2019 | 20 | 0.280 |
Why?
| | Cost-Benefit Analysis | 4 | 2021 | 146 | 0.280 |
Why?
| | Incidence | 2 | 2020 | 827 | 0.270 |
Why?
| | Prospective Studies | 4 | 2019 | 1891 | 0.260 |
Why?
| | Amides | 2 | 2020 | 23 | 0.260 |
Why?
| | Risk Assessment | 3 | 2018 | 804 | 0.260 |
Why?
| | Uracil | 3 | 2019 | 5 | 0.260 |
Why?
| | Ritonavir | 3 | 2019 | 18 | 0.250 |
Why?
| | Prognosis | 3 | 2018 | 1045 | 0.250 |
Why?
| | Chronic Disease | 3 | 2020 | 542 | 0.240 |
Why?
| | Selection Bias | 1 | 2021 | 10 | 0.240 |
Why?
| | Fertility | 1 | 2021 | 16 | 0.230 |
Why?
| | Aminoisobutyric Acids | 2 | 2018 | 3 | 0.230 |
Why?
| | Leucine | 2 | 2018 | 16 | 0.230 |
Why?
| | Graft Survival | 2 | 2019 | 111 | 0.230 |
Why?
| | Pyrrolidines | 2 | 2018 | 20 | 0.230 |
Why?
| | Hepatitis C Antibodies | 1 | 2020 | 6 | 0.220 |
Why?
| | Aged, 80 and over | 8 | 2020 | 5172 | 0.220 |
Why?
| | World Health Organization | 1 | 2020 | 20 | 0.220 |
Why?
| | Tissue Donors | 1 | 2021 | 74 | 0.220 |
Why?
| | End Stage Liver Disease | 1 | 2020 | 17 | 0.210 |
Why?
| | Anilides | 2 | 2019 | 11 | 0.210 |
Why?
| | Hemorrhage | 1 | 2020 | 88 | 0.210 |
Why?
| | Recurrence | 2 | 2011 | 390 | 0.210 |
Why?
| | Consensus | 2 | 2021 | 96 | 0.200 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 179 | 0.200 |
Why?
| | Drug and Narcotic Control | 2 | 2016 | 8 | 0.200 |
Why?
| | Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.200 |
Why?
| | Hepatitis, Autoimmune | 1 | 2019 | 8 | 0.200 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 46 | 0.200 |
Why?
| | Forecasting | 1 | 2019 | 130 | 0.200 |
Why?
| | United States Food and Drug Administration | 2 | 2016 | 78 | 0.190 |
Why?
| | Biomedical Research | 1 | 2019 | 85 | 0.190 |
Why?
| | Transplant Recipients | 1 | 2018 | 18 | 0.190 |
Why?
| | Internationality | 1 | 2018 | 26 | 0.190 |
Why?
| | Logistic Models | 2 | 2010 | 479 | 0.180 |
Why?
| | Follow-Up Studies | 4 | 2015 | 2046 | 0.180 |
Why?
| | RNA, Viral | 3 | 2018 | 170 | 0.180 |
Why?
| | Practice Guidelines as Topic | 3 | 2021 | 389 | 0.180 |
Why?
| | Drug Substitution | 1 | 2017 | 4 | 0.170 |
Why?
| | Critical Pathways | 1 | 2017 | 23 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 527 | 0.170 |
Why?
| | Infant, Newborn | 1 | 2019 | 751 | 0.170 |
Why?
| | Counterfeit Drugs | 1 | 2016 | 2 | 0.160 |
Why?
| | Patient Participation | 1 | 2017 | 51 | 0.160 |
Why?
| | Commerce | 1 | 2016 | 11 | 0.160 |
Why?
| | Ascites | 1 | 2016 | 5 | 0.160 |
Why?
| | Canada | 1 | 2016 | 56 | 0.160 |
Why?
| | Paracentesis | 1 | 2016 | 4 | 0.160 |
Why?
| | Quality Control | 1 | 2016 | 48 | 0.160 |
Why?
| | Fraud | 1 | 2016 | 15 | 0.160 |
Why?
| | Safety | 1 | 2016 | 57 | 0.160 |
Why?
| | Psychometrics | 1 | 2018 | 286 | 0.160 |
Why?
| | Interferons | 1 | 2016 | 17 | 0.160 |
Why?
| | Eclampsia | 1 | 2016 | 2 | 0.160 |
Why?
| | HELLP Syndrome | 1 | 2016 | 2 | 0.160 |
Why?
| | Pre-Eclampsia | 1 | 2016 | 8 | 0.160 |
Why?
| | Drug Approval | 1 | 2016 | 34 | 0.160 |
Why?
| | Time Factors | 3 | 2016 | 1911 | 0.160 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 175 | 0.160 |
Why?
| | Directive Counseling | 1 | 2015 | 15 | 0.150 |
Why?
| | Benchmarking | 1 | 2015 | 29 | 0.150 |
Why?
| | Diffusion of Innovation | 1 | 2015 | 42 | 0.150 |
Why?
| | Hospitalization | 2 | 2016 | 344 | 0.150 |
Why?
| | Benzazepines | 1 | 2015 | 10 | 0.150 |
Why?
| | Isoquinolines | 1 | 2015 | 17 | 0.150 |
Why?
| | Administration, Oral | 1 | 2015 | 165 | 0.150 |
Why?
| | Deficiency Diseases | 1 | 2015 | 2 | 0.150 |
Why?
| | Liver Failure | 1 | 2015 | 13 | 0.150 |
Why?
| | Severity of Illness Index | 1 | 2020 | 1233 | 0.150 |
Why?
| | Zinc | 1 | 2015 | 39 | 0.150 |
Why?
| | Treatment Failure | 2 | 2017 | 188 | 0.150 |
Why?
| | Indoles | 1 | 2015 | 68 | 0.150 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 175 | 0.140 |
Why?
| | Comorbidity | 4 | 2018 | 562 | 0.140 |
Why?
| | Phenotype | 1 | 2015 | 368 | 0.140 |
Why?
| | Off-Label Use | 1 | 2014 | 6 | 0.140 |
Why?
| | Hospitalists | 1 | 2014 | 6 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 361 | 0.140 |
Why?
| | African Americans | 1 | 2021 | 780 | 0.140 |
Why?
| | Internship and Residency | 1 | 2016 | 187 | 0.130 |
Why?
| | Multivariate Analysis | 2 | 2015 | 391 | 0.130 |
Why?
| | Cooperative Behavior | 1 | 2014 | 88 | 0.130 |
Why?
| | Health Care Costs | 1 | 2014 | 82 | 0.130 |
Why?
| | Drug Eruptions | 1 | 2013 | 18 | 0.130 |
Why?
| | Hematologic Diseases | 1 | 2013 | 18 | 0.130 |
Why?
| | Viral Nonstructural Proteins | 3 | 2017 | 9 | 0.130 |
Why?
| | Monitoring, Immunologic | 1 | 2012 | 2 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2014 | 135 | 0.120 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 46 | 0.120 |
Why?
| | Drug Combinations | 3 | 2017 | 88 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 631 | 0.120 |
Why?
| | Cost of Illness | 1 | 2011 | 65 | 0.110 |
Why?
| | Drug Carriers | 1 | 2010 | 9 | 0.110 |
Why?
| | Quality-Adjusted Life Years | 2 | 2021 | 24 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 220 | 0.110 |
Why?
| | Models, Statistical | 1 | 2011 | 146 | 0.100 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 209 | 0.100 |
Why?
| | Odds Ratio | 1 | 2010 | 328 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 594 | 0.100 |
Why?
| | Fluorenes | 2 | 2019 | 3 | 0.090 |
Why?
| | Hemoglobins | 1 | 2008 | 77 | 0.090 |
Why?
| | Valine | 2 | 2019 | 11 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 386 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 957 | 0.080 |
Why?
| | Hospital Costs | 2 | 2016 | 74 | 0.070 |
Why?
| | Pregnant Women | 1 | 2021 | 13 | 0.060 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 4 | 0.050 |
Why?
| | Waiting Lists | 1 | 2019 | 19 | 0.050 |
Why?
| | 2-Naphthylamine | 1 | 2019 | 3 | 0.050 |
Why?
| | Tissue and Organ Procurement | 1 | 2019 | 36 | 0.050 |
Why?
| | Insurance, Major Medical | 1 | 2018 | 1 | 0.050 |
Why?
| | International Normalized Ratio | 1 | 2018 | 32 | 0.050 |
Why?
| | Registries | 1 | 2019 | 203 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 41 | 0.040 |
Why?
| | Uridine Monophosphate | 1 | 2017 | 2 | 0.040 |
Why?
| | Genetic Variation | 1 | 2017 | 117 | 0.040 |
Why?
| | Decision Support Techniques | 1 | 2017 | 54 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 30 | 0.040 |
Why?
| | Serine Proteases | 1 | 2016 | 7 | 0.040 |
Why?
| | Internal Medicine | 1 | 2016 | 30 | 0.040 |
Why?
| | Career Choice | 1 | 2016 | 32 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2017 | 61 | 0.040 |
Why?
| | Cost Savings | 1 | 2016 | 39 | 0.040 |
Why?
| | Pain Management | 1 | 2018 | 140 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2016 | 44 | 0.040 |
Why?
| | Mental Disorders | 1 | 2018 | 202 | 0.040 |
Why?
| | Patient Care Team | 1 | 2017 | 143 | 0.040 |
Why?
| | Curriculum | 1 | 2016 | 153 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2015 | 76 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2018 | 875 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 162 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2016 | 187 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 230 | 0.030 |
Why?
| | Linear Models | 1 | 2015 | 277 | 0.030 |
Why?
| | Databases, Factual | 1 | 2016 | 372 | 0.030 |
Why?
| | Drug Industry | 1 | 2014 | 30 | 0.030 |
Why?
| | Clinical Competence | 1 | 2016 | 268 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2014 | 81 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2014 | 101 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 478 | 0.030 |
Why?
| | Immunoassay | 1 | 2012 | 44 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2012 | 70 | 0.030 |
Why?
| | Inpatients | 1 | 2014 | 147 | 0.030 |
Why?
| | Probability | 1 | 2012 | 107 | 0.030 |
Why?
| | Disease Progression | 1 | 2015 | 851 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 167 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2012 | 1084 | 0.020 |
Why?
|
|
Reau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|